	PTO-144	9 (modified)		Atty. Docket	No.	Serial	No.
	. 10-14-1	) (mounicu)		RIOS:004US		10/66	
		d Publications f		Applicant Adan Rios			
WAS U		ON DISCLOSURE		Filing Date: September 22	2003	Group	4 10
MARIA U	.S. Patent	Documents	Foreig	n Patent Documen			ther Art
	See P	age 1		See Page 1			ee Page 1
						-	
			U.S. Pa	tent Docum	ents		
Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date o
	A	5,849,475	12/15/98	Rovinski et al.	435	5	5/30/95
	A2	5,919,458	7/6/99	Aldovini et al.	424	188.1	6/7/95
	A3	6,017,543	1/25/00	Salk et al.	424	208.1	6/5/95
	A.	6,080,408	6/27/00	Rovinski et al.	424	188.1	^ 6/7/95
			Foreign I	Patent Docui	ments		
Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
							:
	Other A	Art (Includi	ng Autho	or, Title, Date	Pertin	ent Paç	jes, Etc.)
Exam.				Citatio	nn .		
Init.	Ref. Des.						
		"Aronex HIV in Abstract.	hibitor nears p	atent issuance," Reu		edia, Inc., F	ebruary 23, 1996,
Init.	Des.	Abstract.	preliminary c	atent issuance," Reu	ters NewMe		
Init. باد	Des.	Abstract.  "Aronex reports Newswire, Nove Ada, "An Immu	preliminary comber, 12, 199	atent issuance," Reu	HIV integra	se inhibitor,	zintevir (TM)," P.
h 水	Des.	Abstract.  "Aronex reports Newswire, Nove Ada, "An Immu 77-87, Brother e	preliminary comber, 12, 199 nologist's View al., eds., Wilaccines, the in	atent issuance," Reu inical results on its 6, Abstract.	HIV integra:  Textbook of altimore, MI	se inhibitor,  (AIDS Med. D, 1994.	zintevir (TM)," P
Init.	Des.	Abstract.  "Aronex reports Newswire, Nove Ada, "An Immu 77-87, Brother e Ada, "Modern v 335:523-526, 19	preliminary clember, 12, 199 nologist's View at al., eds., Wil accines, the impo	atent issuance," Reu inical results on its 6, Abstract. v of HIV Infection," liams & Wilkens, Barmunological princip	HIV integrae  Textbook of altimore, Miloles of vacci	f AIDS Med D, 1994.	zintevir (TM)," P. icine, Chapter 6, p
Init.	Des. Cl C2 C3	Abstract.  "Aronex reports Newswire, Nove Ada, "An Immu 77-87, Brother e Ada, "Modern v 335:523-526, 19  Albert, et al., "E CTLs," Nature,	preliminary clember, 12, 199 mologist's View at al., eds., Wil accines, the impose of the present al., eds., Wil accines, the impose of the present al., eds., will accine at al., eds., accine	atent issuance," Reu inical results on its 6, Abstract. v of HIV Infection," liams & Wilkens, Barmunological princip	HIV integrated the second of t	se inhibitor,  (AIDS Med. D, 1994.  nation," The ells and inde	zintevir (TM)," Paricine, Chapter 6, paricine, Chapter 6, paricine e Lancet, auce class I-restricte
## ## ## ## ## ## ## ## ## ## ## ## ##	Cl Cl Cl Cl	Abstract.  "Aronex reports Newswire, Nove Ada, "An Immu 77-87, Brother e Ada, "Modern v 335:523-526, 19  Albert, et al., "E CTLs," Nature, Aldrovandl et al 1993.  Amadori et al., '	preliminary clember, 12, 199 mologist's View et al., eds., Will accines, the impose of the property of the pro	atent issuance," Reulinical results on its in 6, Abstract.  of HIV Infection," liams & Wilkens, Burnunological principacquire antigen from 28.	Textbook of altimore, Miles of vaccina apoptotic coll for HIV-1	se inhibitor,  (AIDS Med. D, 1994. nation," The ells and indi	zintevir (TM)," Pricine, Chapter 6, pre Lancet, uce class I-restricted
Init.	Classical Classi	Abstract.  "Aronex reports Newswire, Nove Ada, "An Immu 77-87, Brother e Ada, "Modern v 335:523-526, 19  Albert, et al., "E CTLs," Nature, Aldrovandl et al 1993.  Amadori et al., '	preliminary clember, 12, 199 mologist's View et al., eds., Will accines, the impose of the property of the pro	atent issuance," Reu inical results on its 6, Abstract. v of HIV Infection," liams & Wilkens, Barmunological principal acquire antigen from 98. nu mouse as a mode	Textbook of altimore, Miles of vaccina apoptotic coll for HIV-1	se inhibitor,  (AIDS Med. D, 1994. nation," The ells and indi	zintevir (TM)," Pricine, Chapter 6, pre Lancet, uce class I-restricted
Init.	Cl C	Abstract.  "Aronex reports Newswire, Nove Ada, "An Immu 77-87, Brother e Ada, "Modern v 335:523-526, 19  Albert, et al., "E CTLs," Nature, Aldrovandl et al 1993.  Amadori et al., '	preliminary clember, 12, 199 mologist's View et al., eds., Will accines, the impose of the property of the pro	inical results on its of the control	Textbook of altimore, Miles of vaccina apoptotic coll for HIV-1	Se inhibitor,  (AIDS Med. D, 1994. Ination," The ells and indi infection," / yte function mmunol, 8:2	zintevir (TM)," Picine, Chapter 6, pe Lancet, uce class I-restrict Vature, 363:732-73 and 249-254, 1996.

For	rm PTO-1449 (modified)		Atty. Docket No.	Serial No.
	t of Patents and Publications for		RIOS:004USC2 Applicant Adan Rios	10/667,534
A. A	(Use several sheets if necessa	ry)	Filing Date: September 22, 2003	Group: Unknown (648
EL RECEMBER	U.S. Patent Documents	Foreign 1	Patent Documents	Other Art
	See Page 1		See Page 1	See Page 1

Exam. Init.	Ref. Des.	Citation
<b>*</b>	С	Baba et al., "Pathogenicity of live, attenuated hiv after mucosal infection of neonatal macaques," Science, 267:1820-1825, 1995.
*	O	Bachmann and Zinkernagel, "Neutralizing antiviral b cell responses," Annu. Rev. Immunol., 15:235-270, 1997.
χ.	CIO	Balter, "A cluster of Europe's aids research stars," Science, 280:1862, 1998c.
*	C 1	Balter, "Duo brings hope of immune restoration," Science, 280:1861, 1998b.
*	CI2	Balter, "Global program struggles to stem the flood of new cases," <i>Science</i> , 280:1863-1864, 1998d.
#	C13	Balter, "HIV incidence: 'more serious than we imagined'," Science, 280:1864, 1998e.
7	C14	Balter, "Modest briton stirs up storm with views on role of CTLs," Science, 280:1860-1861, 1998a.
vc	C15	Balter, "T cell production slowed, not exhausted?" Science, 283(5400):305-306, 1999.
*	C15	Baltimore, "Lessons from people with nonprogressive hiv infection," The New England J. of Medi., 332:259-260, 1995.
¥	CIV	Banchereau and Steinman, "Dendritic cells and the control of immunity," <i>Nature</i> , 392:245-252, 1998.
٤	C18	Barnard et al., "The thiocarboxanilide nonnucleoside uc781 is a tight-binding inhibitor of hiv-1 reverse transcriptase," Biochem., 36:7786-7792, 1997.
×	C19	Barr, "Vaccines for HIV, HIV therapeutic vaccines: the next phase," GMHC's Treat. Iss., Vol. 7, No. 5, 1993.
*	C20	Bender et al., "Inactivated influenza virus, when presented on dendritic cells, elicits human cd8 <sup>+</sup> cytolytic t cell responses," J. Exp. Med., 12:1663-1671, 1995.
*	C21	Berger et al., "A new classification of HIV-1," Nature, 391:340, 1998.
*	C22	Blauvelt et al., "Productive infection of dendritic cells by hiv-1 and their ability to capture virus are mediated through separate pathways," The J. of Clin. Invest., 100:2043-2053, 1997.
Уķ	C23	Bolognesi and Matthews, "Viral envelope fails to deliver?," Nature, 391:638-639, 1998.

Examiner:		DATE CONSIDERED: 10 01	106
EXAMINER: INITIAL IF	EFERENCE CONSIDERED, WHETHER OR NOT CIT.	ATION IS IN CONFORMANCE WITH MPEP609	; DRAW LINE THROUGH
	ORMANCE AND NOT CONSIDERED. INCLUDE COP		

				1 460 5 01 10
Form P	TO-1449 (modified)		Atty. Docket No.	Serial No.
			RIOS:004USC2	10/667,534
List of P	atents and Publications f	Applicant's	Applicant	
OIPE			Adan Rios	
/ Syri	ORMATION DISCLOSURE S	TATEMENT		
( TE 0 1 200 )	(Use several sheets if necessa		Filing Date: September 22, 2003	Group: Unknown 1648
3, 30.5	S. Patent Documents	Foreign l	Patent Documents	Other Art
PAREMARIE	See Page 1	S	See Page 1	See Page 1
		_	-	

Exam. Init.	Ref. Des.	Citation
#	C24	Bombil et al., "A promising model of primary human immunization inhuman-scid mouse," Immunobiology, 195:360-375, 1996 (Abstract).
*†	C25	Borkow et al., "Chemical barriers to human immunodeficiency virus type 1 (hiv-1) infection: retrovirucidal activity of uc781, a thiocarboxanilide nonnucleoside inhibitor of hiv-1 reverse transcriptase," J. of Virol., 71:3023-3030, 1997.
<b>-</b> 4	C26	Borkow et al., "Chemical barriers to Human Immunodeficiency Virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor or HIV-1 reverse transcriptase," <i>Journal of Virology</i> 71(4):3023-3030, 1997.
•≮	C27	Borkow et al., "Inhibition of the ribonuclease H and DNA polymerase activities of hiv-1 reverse transcriptase by n-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone," Biochemistry, Abstract, 36(11):3179-3185, 1997.
ب	C28	Bryson et al., "Clearance of HIV infection in a perinatally infected infant," The New Engl. J. of Med., 332:833-838, 1995.
7	C29	Buckheit et al., "Efficacy pharmacokinetics and in vivo anti-HIV activity of the highly potent oxathiin carboxanilide analog, UC781," Journal of Molecular Medicine 75(7):b212-b213, 1997.
¥	C30	Buckheit et al., "Efficacy, Pharmacokinetics, and in Vivo Antiviral Activity of UC781, a Highly Potent, Orally Bioavailable Nonnucleoside Reverse Transcriptase Inhibitor of HIV Type 1," Aids Res. and Hu. Retro., 13:789-796, 1997.
£	С31	Burr, "Of AIDS and altruism," U.S. Nws. & W. Rpt., pp. 59-61, April 6, 1998.
7	C32	Burton and Montefiori, "The antibody response in HIV-1 infection," Aids, 11:S87-S98, 1997.
* .	C33	Cao et al., "Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection," The New Engl. J. of Med., 332:201-216, 1995.
×.	C34	Carlson et al., "Vaccine Protection of Rhesus Macaques Against Simian Immunodeficiency Virus Infection," AIDS Res. and Hum. Retroviruses, 6:1239-1246, 1990.
7	C35	Cavert and Haase, "A national tissue bank to track HIV eradication and immune reconstitution," Science, 280:1865-1866, 1998.
À	<b>G</b> 6	Cella et al., "Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells," Nature, 388:782-792, 1997.

Examiner:	Dar	TE CONSIDERED:	10/01/06
EXAMINER: INITIAL IF REFERENCE	CONSIDERED, WHETHER OR NOT CITATION I	S IN CONFORMANCE WITH	MPEP609; DRAW LINE THROUGH

							Page 4 of 10
	Form P	TO-144	9 (modified)		Atty. Docket No.		Serial No.
					RIOS:004USC2		10/667,534
_	List of P	atents an	d Publications for A	Applicant's	Applicant		
OIPE	INF	ORMATIC	ON DISCLOSURE ST	ATEMENT	Adan Rios		
ESC 0 1	THE STATE OF	(Use s	everal sheets if necessary	y)	Filing Date: September 22, 2003		Gr up: Unknown 1648
	Į Ü.	S. Patent	Documents	Foreign P	atent Documents	[	Other Art
Fee	CARRY.	See P	age 1	Se	ee Page 1		See Page 1
RACE							
		Other.	Art (Including	g Author,	Title, Date Per	tinen	t Pages, Etc.)
	Exam. Init.	Ref. Des.			Citation		,
	÷	C37	Chowdhry, "Photo 1979.	affinity labeling	of biological systems,"	' Ann. Re	v. Biochem., 48:293-325,
	<i>&gt;</i>	C38	Clerici et al., "HIV contaminated blood	-specific t-helped," <i>JAMA</i> , 271:4	er activity in seronegativ 12-46, 1994.	ve health	care workers exposed to
	<i></i>	C39			of human immunodefic , 332(24):1646-1647, 19		rus type I infection," The
	4	C40	Cohen et al., "Chainhibitor of human 266:14670-14674,	immunodeficie	the binding site for nevi ncy virus type-1 reverse	rapine (b transcri	oi-rg-587), a nonnucleoside ptase," <i>J. of Biol. Chem.</i> ,
	#	C41	Collins et al., "HIV lymphocytes," Nati	/-1 Nef protein   ure, 391:397-40	protects infected primar 2, 1998.	y cells ag	gainst killing by cytotoxic T
	*	C42	Colonna, "Unmask	ing the killer's a	ccomplice," Nature, 39	1:642-64	4, 1998.
	*	C4B			of TH1 and TH2 CD4, 15:297-322, 1997.	T cell re	esponses: the alternative
	*	C44	Daniel, et al., "A ro	ole for DNA-PK	in retroviral DNA inte	gration,"	Science, 284:644-647, 1999.
•	*	C45	DeNoon, "AIDS T AIDSWEEKLY Plu		ntegrase inhibitor enhar , 1998, Abstract.	nces other	r anti-HIV drugs,"
	ķ	C46	Doherty and Zinker Lancet, 1406-1409	rnagel, "A Biolo ), 1975.	ogical role for the major	histocor	mpatibility antigens," The
	. <del>}*</del>	C47			ecificity of the Cell Medee, Press Release Octobe		nmune Defense," <i>The Nobel</i> 6.
	*	C48	Dragic et al., "HIV Therapy, 7(3):2-12		ateways to the cell," HI	V Advan	ces in Research and
		C49	D'Souza et al., "Ne antibodies," AIDS,		orimary HIV-1 isolates t 5.	by anti-er	nvelope monoclonal
	木	C50	Dutton et al., "T ce	ll memory," An	nu. Rev. Immunol., 16:2	201-223,	1998.
	#	C51	Emerman and Mali biology," Science,	m, "HIV-1 regu 280:1880-1884,	latory/accessory genes: 1998.	keys to 1	unraveling viral and host cell

Examiner:		DATE CONSIDERED: 10	01	06	
<b>EXAMINER: INITIAL IF REFERENCE</b>	CONSIDERED, WHETHER OR NOT CIT	ATION IS IN CONFORMANCE WITH MPE	2609; D	RAW LINE THROUGH	
CITATION IF NOT IN CONFORMANCE	AND NOT CONSIDERED. INCLUDE COP	Y OF THIS FORM WITH NEXT COMMUNIC	NOITA	TO APPLICANT.	

					Page 5 of 10
Form P	TO-144	9 (modified)		Atty. Docket No.	Serial No.
				RIOS:004USC2	10/667,534
	atents an	d Publications for	Applicant's	Applicant Adan Rios	
*ONFO	ORMATIC	ON DISCLOSURE ST	<b>CATEMENT</b>	Adan Ros	
ma 55		several sheets if necessar	•	Filing Date:	Group:
Au.	· · · · · · · · · · · · · · · · · · ·	Documents	<del></del>	September 22, 2003 Patent Documents	Other Art
"BRONG"		Page 1	1	ee Page 1	See Page 1
GU.					
	Other.	Art (Includin	g Author,	Title, Date Per	tinent Pages, Etc.)
Exam. Init.	Ref. Des.			Citation	
*	C52	Excler and Plotkir 11:S127-S137, 19		post concept applied to I	HIV preventive vaccines," Aids,
٦.	C53	Ferrari, "Clade B- in uninfected volu	based HIV-1 va inteers," <i>Proc. N</i>	ccines elicit cross-clade latl. Acad. Sci. USA, 94:	cytotoxic T lymphocyte reactivities 1396-1401, 1997.
ょ	C54				nhibitors of hiv-1 reverse he enzyme," <i>Biochem.</i> , 34:4346-
	C55		act with differen		nhibitors of HIV-1 reverse he enzyme," <i>Biochemistry</i>
	C56	Frankel and Youn 1998.	g, "HIV-1: fiftee	en proteins and an RNA,	" Annu. Rev. Biochem., 67:1-25,
	C57	Gibbons et al., "Ti investigation of m 1997.	hy/Liv-SCID-Huucosal transmiss	u mice implanted with his sion of HIV," Aids Res. of	uman intestine: an in vivo model for and Hum. Retrovir., 13:1453-1460,
	C58	Glenn et al., "Skir	immunization	made possible by cholera	a toxin," Nature, 391:851, 1998.
	C59	Gotch et al., "New Aids, 11:S99-S107		n cellular immune respon	nses to HIV and T-cell epitopes,"
	C60	Graham and Wrigi 1995.	ht, "Drug therap	y, candidate aids vaccino	es," Drug Ther., 333:1331-1339,
	C61	Guidotti, et al., "V infection," Science			ected cells during acute HBV
	C62			ducts," Textbook of AID. ilkens, Baltimore, MD,	S <i>Medicine</i> , Chapter 3, pp. 21-43, 1994.
·	СВ			oside inhibitors of hiv-1 nones," J. of Med. Chem	reverse transcriptase, 1. tricyclic ., 34:2231-2241, 1991.
	C64			ic sequela in rhesus mac , Internet: www.sciencer	raques infected with CCR5 or mag.org, 1999.
	C65	Ho, "Toward HIV	eradication or re	emission: the tasks ahead	d," Science, 280:1866-1867, 1998.
25356361.1					,

Form PTO-1449 (modified)		Atty. Docket No.	Serial No.
	•	RIOS:004USC2	10/667,534
Signification of Patents and Publications for	Applicant's	Applicant	
(Free)		Adan Rios	
Conformation Disclosure S	TATEMENT		
		Filing Date:	Group:
(Use several sheets if necessa	iry)	September 22, 2003	Linknown Would
(Use several sheets if necessary U.S. Patent Documents	Foreign I	Patent Documents	Other Art
See Page 1	S	ee Page 1	See Page 1

Exam. Init.	Ref. Des.	Citation
	C66	Hong et al., "Discovery of HIB-1 integrase inhibitors by pharmacophore searching," J. Med. Chem., 40:930-936, 1997, Abstract.
	C67	Huang et al., "Effect of mutations in the nucleocapsid protein (NCP7) upon PR160(GAG-POL) and trna (lys) incorporation into human immunodeficiency virus type 1," J. of Virology, 71(6):4378-4384, 1997, Abstract.
	C68	Huston, "The biology of the immune system," JAMA, 278:1804-1813, 1997.
	C69	Jawetz eds., et al., "Serologic diagnosis & immunologic detection of virus infections," Lange Medical Book, 17th ed., Appleton & Lange, Norwalk, CT, pp. 371-380, 1987.
	C70	Jing et al., "Potassium-induced loop conformational transition of a potent anti-HIV oligonucleotide," J. Biomol Struct. Dyn., 15:573-583, 1997, Abstract.
	C71	Jockusch et al., "Photo-induced inactivation of viruses: adsorption of methylene blue, thionine, and thiopyronine on Qβ bacteriophage," Proc. Natl. Acad. Sci. USA, 93:7446-7451, 1996.
	C72	Kim et al., "Limitation of Hu-PBL-scid mouse model in direct application to immunotoxicity assessment," J. Pharmacol Toxicol Methods, 37:83-89, 1997 (Abstract).
	C73	Knight and Patterson, "Bone marrow-derived dendritic cells, infection with human immunodeficiency virus, and immunopathology," Annu. Rev. Immunol., 15:593-615, 1997.
	C14	Kollmann et al., "Disseminated human immunodeficiency virus 1 (hiv-1) infection in scid-hu mice after peripheral inoculation with hiv-1," J. Exp. Med., 179:513-522, 1994.
	C75	Korber, et al., "Limitations of a molecular clock applied to considerations of the origin of HIV-1," Science, 280:1868-1871, 1998.
	C76	LaCasse et al., "Fusion-competent vaccines: broad neutralization of primary isolates of HIV," Science, 283:357-362, 1999.
	C77	Lamb-Wharton et al., "Primate models of AIDS vaccine development," Aids, 11(suppl A):S121-S126, 1997.
	C78	Lanzavecchia, "Licence to kill," Nature, 393:413-414, 1998.
	C79	Letvin, "Progress in the development of an HIV-1 vaccine," Science, 280:1875-1880, 1998.
	C80	Letvin, "Vaccines against human immunodeficiency virus progress and prospects," N.E. J. of Med., 329:1400-1405, 1993.

25356361.1			. 1
Examiner:		DATE CONSIDERED:	(2 ox 06
	ERERENCE CONSIDERED, WHETHER OR NOT C RMANCE AND NOT CONSIDERED. INCLUDE C		

Form	PTO-1449 (modified)		Atty. Docket No. Serial No.		
			RIOS:004USC2 10/667,534		
CIPE	Patents and Publications for	••	Applicant Adan Rios		
, IN	FORMATION DISCLOSURE S	TATEMENT	EW D		
	(Use several sheets if necessa	гу)	Filing Date: September 22, 2003	Group: Unknown (648	
RICENARK OFFICE	J.S. Patent Documents	Foreign	Patent Documents	Other Art	
See Page 1		S	See Page 1	See Page 1	

Exam. Init.	Ref. Des.	Citation
C81		Lin et al., "Photoaffinity labeling by 4-thiodideoxyuridine triphosphate of the HIV-1 reverse transcriptase active site during synthesis," J. Bio. Chem., 273:997-1002, 1998.
	C82	Loetscher et al., "CCR5 is characteristic of Th1 lymphocytes," Nature, 391:344-345, 1998.
	C83	Long, "Signal sequences stop killer cells," Nature, 391:740-741, 1998.
	C84	Luster, "Chemokines - chemotactic cytokines that mediate inflammation," New Engl. J. of Med., 338:436-445, 1998.
	C85	Martinez, "Positive + Positive: Sex and the risk of reinfection," Center for AIDS Hope & Remembrance, 3(6):3-5, 1997.
	C86	Matthews et al., "Preliminary studies of photoinactivation of human immunodeficiency virus in blood," Transfusion, 31:636-641, 1991.
	C87	Mazumder et al., "Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action," J. Med. Chem., 40:3057-3063, 1997, Abstract.
	C38	McIntosh and Burchett, "Clearance of HIV-lessons from newborns," <i>The New Engl. J. of Med.</i> , 332:883-884, 1995.
•	C39	McMichael and Phillips, "Escape of human immunodeficiency virus from immune control," Annu. Rev. Immunol., 15:271-296, 1997.
	C90	Meldorf and Corey, "HIV vaccines: vombination and prime-boost strategies," HIV, Vol. 7, No. 1, pp. 24-29.
	<b>C</b> 91	Montefiori and Moore, "Magic of the occult?," Science, 283:336-337, 1999.
	C92	Murphy et al., "The huPBL-SCID mouse as a means to examine human immune function in vivo," Semin Immunol, 8:233-241, 1996 (Abstract).
	093	Musey et al., "Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection," The New England J. of Med., 337:1267-1274; 1305-1308, 1997.
	C94	Namikawa et al., "Infection of the SCID-hu mouse by HIV-1," Science, 242-1684-1686, 1988.
	C95	NIMH Trial Group, "The NIMH multisite HIV prevention trial: reducing HIV sexual risk behavior," Science, 280:1889-1894, 1998.

25356361.1		. 1
Examiner:	DATE CONSIDERED:	600106
	NOT CITATION IS IN CONFORMANCE WITH N	

	<u>·</u>				1 4 5 6 6 7 7		
Form	PTO-14	19 (modified)		Atty. Docket N .	Serial N .		
	List of Patanta and Publications for Applicants			RIOS:004USC2 10/667,534			
List of	List of Patents and Publications for Applicant's			Applicant			
Information Disclosure Statement				Adan Rios			
11	ii Oldwix i i	ON DISCLOSURE S	ATEMENT	Filing Date:	Group:		
~~~	(Use	several sheets if necessa	гу) .	September 22, 2003	Unknown 1648		
1	U.S. Paten	t Documents	Foreign I	atent Documents	Other Art		
	See .	Page 1	s	ee Page 1	See Page 1		
A.							
200 E	Other	Art (Includin	g Author,	Title, Date Per	tinent Pages, Etc.)		
Exam Jen.	. Ref. Des.			Citation	·		
alk Or	C96	Pamer and Cressy Immunol., 16:323		ns of MHC class I-restri	cted antigen processing," Annu. Rev.		
	C9*			ts with long-term nonpro , 332(4):209-216, 1995.	gressive human immunodeficiency		
	C98 Pauwels et al., "Potent and select TIBO derivatives," Letters To Na			ive inhibition of HIV-1 replication in vitro by a novel series of sture, 343:470-474, 1990.			
	C99	C99 Peeters et al., "Virological and polymerase chain reaction studies of HIV-1/HIV-2 dual infection in Côte d'Ivoire," Lancet, 340:339-340, 1992.					
	C100	Perrin and Telenti Science, 280:1871		t failure: testing for HIV	resistance in clinical practice,"		
	C10	Phoolcharoen, "H 280:1873-1874, 1		tion in Thailand: success and challenges," Science, ction," JAMA, 278:58-62, 1997.			
	C102	Quinn, "Acute pri	mary HIV infec				
***************************************	C103	Ren et al., "Crysta derivatives," Bioc		dritic cell can be a temporal bridge between a CD4 <sup>+</sup> T-helper			
	C104	Ridge et al., "A co					
	C105	Robinson, "DNA	vaccines for im	nunodeficiency viruses,'	' Aids, 11:S109-S119, 1997.		
C106 Robinson, "L-chicoric acid, an in			coric acid, an in	nhibitor of human immunodeficiency virus type 1 (HIV-1) ro anti-HIV-1 effect of zidovudine plus a protease inhibitor			
	C107 Rosenberg et al., "Vigorous HIV-viremia," Science, 278:1447-1450				conses associated with control of		
C108 Rossio et al., "Inactivation of Hum Preservation of Conformational ar Virology, 72(10):7992-8001, 1998			onformational ar	nd Functional Integrity o			
	C109			ical activity of novel nonnucleoside inhibitors of hiv-1 reverse enzimidazoles," J. of Med. Chem., 40:4199-4205, 1997.			

Examiner:	<u>}</u>	DATE CONSIDERED:	0106
EXAMINER: INITIAL IF REFERENCE	CONSIDERED, WHETHER OR NOT CI	TATION IS IN CONFORMANCE WITH MPE	P609; DRAW LINE THROUGH
CITATION IF NOT IN CONFORMANCE.	AND NOT CONSIDERED. INCLUDE CO	PY OF THIS FORM WITH NEXT COMMUNI	CATION TO APPLICANT.

			1460 / 1	
Form PTO-1449 (modified)		Atty. Docket No.	Serial No.	
		RIOS:004USC2 10/667,534		
List of Patents and Publications for	or Applicant's	Applicant		
INFORMATION DISCLOSURE		Adan Rios	•	
INFORMATION DISCLOSURE	STATEMENT			
જો જો		Filing Date:	Gr up:	
(Use several sheets if neces	sary)	September 22, 2003	Unknown 1648	
<b>W</b> U.S. Patent Documents	Foreign	Patent Documents	Other Art	
See Page 1		See Page 1	See Page 1	

Exam. Init.	Ref. Des.	Citation
C110		Schacker et al., "Annals of internal medicine, biological and virologic characteristics of primary HIV infection," Ann. Intern. Med., 128:613-620, 1998.
	C111	Schmitz et al., "Control of viremia in simian immunodeficiency virus infection by cd8 <sup>+</sup> lymphocytes," Science, 283:857-860, 1999.
	C112	Schultz, "Changing paradigms for an HIV vaccine," In: Adv. in Exper. Med. and Biol., 397:79-90, 1996.
	C113	Schumacher, "Immunology: accessory to murder," Nature, 398:26-27, 1999.
	C114	Sigal et al., "Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen," Nature, 398:77-80, 1999.
	C115	Smart, "The first integrase inhibitor," GMHC Treat Issues, 10:8-9, 1996, Abstract.
	C116	Smerdon et al., "Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1," Proc. Natl. Acad. Sci., USA, 91:3911-3915, 1994.
	C117	Suhadolnik et al., "Photolabeling of the enzymes of the 2-5A synthetase/RNase L/p68 kinase antiviral systems with azido probes," <i>Progress in Molecular and Subcellular Biology</i> 14:260-275, 1994.
	C118	Sylwester et al., "CD4 <sup>+</sup> T-Lymphocyte Depletion in Human Lymphoid Tissue Ex Vivo Is Not Induced by Noninfectious Human Immunodeficiency Virus Type 1 Virions," J. Virology, 72(11):9345-9347, 1998.
	C119	Tang and Cyster, "Chemokine up-regulation and activated T cell attraction by maturing dendritic cells," Science, 284:819-822, 1999.
	C120	Tarasiev et al., "Photochemoinactivation: a way to AIDS vaccine?,"America Online: ARIOS927, Vol. 9 Issue/Part/Supplement 1, 1993 (Abstract).
	C121	Walker, "Immunopathogenesis and immune reconstitution in HIV disease," <i>Intl. Aids SocUSA</i> , 6:4-7, 1999.
	C122	Wallace et al., "Preclinical pharmacology of an anti-HIV oligonucleotide," Int. Conf. AIDS, 11:314, 1996, Abstract.
	C123	Watts, "Capture and processing of exogenous antigens for presentation on MHC molecules," Annu. Rev. Immunol., 15:821-850, 1997.

Examiner:	DATE CONSIDERED: (0) 06	
	OT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH	
CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLU	DE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

Form PTO-1449 (modified)			Atty. Docket No. Serial N . RIOS:004USC2 10/667,534		
	t of Patents and Publications for Information Disclosure St		Applicant Adan Rios		•
TO O TO STATE OF THE STATE OF T	(Use several sheets if necessar	(Y)	Filing Date: September 22, 2003	Group:	
CENARK OFF	U.S. Patent Documents See Page 1	_	Patent Documents see Page 1	Other Art  See Page 1	

Exam. Ref. Init. Des.		Citation
	C124	Wu et al., "A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site," Biochem., 30:2022-2026, 1991.
C125		Wyatt and Sodroski, "The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens," Science, 280:1884-1888, 1998.
C126 C127 C128 C129 C130		Yang et al., "Neutralizing antibodies against hiv determined by amplification of viral long terminal repeat sequences from cells infected in vitro by nonneutralized virions," J. of Acq. Imm. Defic. Synd. and Hum. Retro., 17:27-34, 1998.
		Zhang et al, "Nascent Human Immunodeficiency Virus Type 1 Reverse Transcription Occurs within an Enveloped Particle," J. Virology, 69(6):3675-3682, 1995.
		Zhao, et al., "Hydrazide-containing inhibitors of HIV-1 integrase," J. Med. Chem., 40:937-941, 1997, Abstract.
		Zinkemagel and Doherty, "Immunological surveillance against altered self components by sensitized T lymphocytes in lymphocytic choriomeningitis," <i>Nature</i> , 251:547-548, 1974.
		Zinkernagel and Doherty, "MHC-restricted cytotoxic t cells: studies on the biological role of polymorphic major transplantation antigens determining t-cell restriction-specificity, function, and responsiveness," Advan. In Immunol., New York, Academic Press, 27:51-177, 1979.
	C131 .	Zinkernagel and Doherty, "Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system," Nature, 248:701-702, 1974.
	C132	PCT Search Report dated July 7, 1999

25356361.1	*			. 1	ı
Examiner:		DATE CONSIDERED:	ю	01	oy
	REFERENCE CONSIDERED, WHETHER OR NOT CIT.				